Investor Relations

Alexza is a pharmaceutical development company focused on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system, or CNS, conditions. All of our product candidates are based on our proprietary technology, the Staccato® system. The Staccato system, vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Because of the particle size of the aerosol, the drug is quickly absorbed through the deep lung into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous, or IV, administration but with greater ease, patient comfort and convenience.

Webcast - Replay Q1 2013 Alexza Pharmaceuticals, Inc. Earnings Conference Call 05/14/13 at 5:00 p.m. ET

Stock Quote ALXA (Common Stock) Exchange NASDAQ (US Dollar) Price $4.39 Change (%)   0.04 (0.90%) Volume 536,012 Data as of 05/17/13 4:00 p.m. ET Minimum 20 minute delay Refresh quote

What's New   Alexza Pharmaceuticals, Inc. Form 8937

Recent News More >> Date Title   05/14/13 Alexza Reports 2013 First Quarter Financial Results 05/08/13 Alexza Announces Conference Call to Discuss Agreement with Teva to Market ADASUVE® in the U.S. 05/08/13 Teva and Alexza Announce Teva's License to Market ADASUVE® in the U.S. 05/06/13 Alexza Pharmaceuticals to Present at Antiepileptic Drug and Device Trials (AED) XII Conference Highlighting Advances in the Treatment of Epilepsy

Upcoming Events More >> There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.